Replies to post #155298 on Cytodyn Inc (CYDY)

[DonDonDonDon]

Panning out fine??!! It's failed twice already, changing the trial after the first failure is somewhat understandable but the second time is a hail mary.

It didn't fail twice. It has changed its primary endpoint twice. The DSMC only allows a trial to change its primary endpoint if they believe the trial is showing promise. It is a good thing, not a bad thing.

Results from HGEN's interim analysis explained in the below link. And remember, the 37% efficacy that lenzilumab demonstrated is the whole trial, not a 62 patient slice.

https://www.biospace.com/article/releases/humanigen-announces-positive-interim-phase-3-data-of-lenzilumab-in-patients-hospitalized-with-covid-19/